EU court should help companies recoup investment on paediatric trials with maximum patent extension possible, says lawyer
This article was originally published in Scrip
Executive Summary
The Court of Justice of the European Union should go beyond the recent advocate general's opinion on negative term supplementary protection certificates (SPCs) and help pharmaceutical companies recoup part of their investments on paediatric trials, says Maria Isabel Manley, head of regulatory practice at the UK law firm, Bristows.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.